POZEN Inc.  

(Public, NASDAQ:POZN)   Watch this stock  
Find more results for POZN
7.36
+0.08 (1.10%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.22 - 7.47
52 week 4.92 - 9.90
Open 7.34
Vol / Avg. 0.00/331,451.00
Mkt cap 227.09M
P/E     -
Div/yield 1.75
EPS -0.27
Shares 30.85M
Beta 1.92
Inst. own 60%
Aug 7, 2014
Q2 2014 Pozen Inc Earnings Call - 11:00AM EDT - Add to calendar
Aug 7, 2014
Q2 2014 POZEN Inc. Earnings Release - 9:30AM EDT - Add to calendar
Jun 4, 2014
POZEN Inc. Annual Meeting of Stockholders
May 14, 2014
POZEN Update Conference Call - Webcast
May 8, 2014
Q1 2014 POZEN Inc. Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 POZEN Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 38.48% -161.87%
Operating margin 38.38% -162.60%
EBITD margin - -162.32%
Return on average assets 34.38% -26.75%
Return on average equity 58.82% -32.80%
Employees 16 -
CDP Score - -

Address

SUITE 400, 1414 RALEIGH ROAD
CHAPEL HILL, NC 27517
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

POZEN Inc. (POZEN), is a pharmaceutical company focused on transforming medicine. The Company had developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet is the brand name for the product combining sumatriptan 85 milligram, formulated with RT Technology and naproxen sodium 500 milligram in a single tablet designed for the acute treatment of migraine. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. On November 23, 2011, the Company entered into a Purchase and Sale Agreement with CPPIB Credit Investments Inc (CII,), pursuant to which it sold, and CII purchased, its right to receive future royalty payments arising from United States sales of MT 400, including Treximet.

Officers and directors

John R. Plachetka Pharm.D. Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
William L. Hodges CPA Chief Financial Officer, Senior Vice President - Finance and Administration
Age: 59
Bio & Compensation  - Reuters
Gilda M. Thomas J.D. Senior Vice President, General Counsel
Age: 59
Bio & Compensation  - Reuters
Dennis L. McNamara Senior Vice President, Chief Business Officer
Age: 48
Bio & Compensation  - Reuters
John E. Barnhardt CPA Vice President - Finance and Administration
Age: 64
Bio & Compensation  - Reuters
John G. Fort M.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Kenneth B. Lee Jr. Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Neal F. Fowler Independent Director
Age: 52
Bio & Compensation  - Reuters
Arthur S. Kirsch Independent Director
Age: 62
Bio & Compensation  - Reuters
Seth A. Rudnick M.D. Independent Director
Bio & Compensation  - Reuters